[人表皮生长因子受体2阳性乳腺癌：标准治疗与双重靶向治疗]
[HER2-positive breast cancer: standard and double targeted therapy].
作者信息
Semiglazov V F, Bozhok A A, Semiglazova T Iu, Vasil'ev A G, Manikhas A G, Semiglazov V V, Bessonov A A, Nikolaev K S
出版信息
Vopr Onkol. 2013;59(3):341-6.
PMID:23909035
Abstract
Neoadjuvant systemic therapy is frequently used option for the systemic treatment for breast cancer. Inclusion in the regimen of targeted drugs as trastuzumab (Herceptin) and pertuzumab significantly improves outcomes in HER2-positive breast cancer patients. A certain part of HER2-positive patients can be cured by using only targeted drugs without chemotherapy.
摘要
新辅助全身治疗是乳腺癌全身治疗中常用的选择。将曲妥珠单抗（赫赛汀）和帕妥珠单抗等靶向药物纳入治疗方案可显著改善HER2阳性乳腺癌患者的预后。一部分HER2阳性患者仅使用靶向药物而不进行化疗即可治愈。
Zotero 插件